- $19 million of series 2017A revenue bonds
- $86 million of series 2017C revenue bonds
The rating affirmations are based on a number of factors, including the cancer center’s national standing as a leading research institute, strong unrestricted liquidity and strong fundraising capabilities.
The outlook is stable, reflecting Moody’s Investors Service’s expectation the cancer center will improve its liquidity supporting debt and operations, its growing research activity and positive operating cash flow generation for adequate debt service.
More articles on healthcare finance:
S&P places MetroHealth System’s ‘A-‘ bonds on CreditWatch
S&P lowers North Oaks Health System’s rating to ‘BB+’ on select bonds
Fitch assigns ‘AA-‘ rating to University Medical Center of El Paso’s bonds
